Processa Pharmaceuticals, Inc.
Pharmaceutical drug products for unmet medical needs
Follows are private to you and power your alerts
Updated · processapharmaceuticals.com
- Sector
- Biotech
- Headquarters
- HANOVER, MD
- Founded
- 2011
- Latest Form D
- $10.2M, Feb 2021
- Total capital
- $18.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $18.7M
- 14 Form D · last Feb 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 14th filing$10.2M
- Private capital raisedForm D · SEC · 13th filing$2.5M
- Private capital raisedForm D · SEC · 12th filing$2.6M
- Private capital raisedForm D · SEC · 11th filing$26K
- Private capital raisedForm D · SEC · 10th filing$90K
- Private capital raisedForm D · SEC · 9th filing$75K
- Private capital raisedForm D · SEC · 8th filing$174K
- Private capital raisedForm D · SEC · 7th filing$175K
- Private capital raisedForm D · SEC · 6th filing$250K
- Offering registeredForm D · SEC · 5th filing$5.4M
- Offering registeredForm D · SEC · 4th filing$4.5M
- Private capital raisedForm D · SEC · 3rd filing$1M
- Private capital raisedForm D · SEC · 2nd filing$1.5M
- Offering registeredForm D · SEC · 1st filing$3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- David YoungExecutive Officer, DirectorNamed in SEC Form D filings
- Geraldine W. PannuDirectorNamed in SEC Form D filings
- Helen W. PentikisExecutive OfficerNamed in SEC Form D filings
- James W. StankerExecutive OfficerNamed in SEC Form D filings
- Justin YorkDirectorNamed in SEC Form D filings
- Justin W. YorkeDirectorNamed in SEC Form D filings
Show all 12 people
- Khalid W. IslamDirectorNamed in SEC Form D filings
- Michael W. FloydExecutive OfficerNamed in SEC Form D filings
- Patrick LinExecutive OfficerNamed in SEC Form D filings
- Sian W. BigoraExecutive OfficerNamed in SEC Form D filings
- Virgil W. ThompsonDirectorNamed in SEC Form D filings
- Wendy W. GuyExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingMethods Of Personalizing Cancer TreatmentUSPTOApplication PCTUS2024037783
- PendingMethods Of Personalizing Cancer TreatmentUSPTOApplication 63513514
Related companies, and why
- Olema PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Veltion Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Corridor Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- IRIDIA, INC.Similar federal contract value in Biotech · null in contracts
- Bluejay TherapeuticsSimilar federal contract value in Biotech · null in contracts
- STINGINN, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .